ABL1 and acute lymphoblastic leukemia: Based on this consideration, the EsPhALL 2017/COG AALL1631 was amended in 2021 to also include a cohort of patients with ABL-class fusion positive ALL as eligible to participate in the chemotherapy backbone randomization.